Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO 2020 Expert Video Report on CDK4 6i in the adjuvant treatment of breast cancer

Reporting from ESMO Virtual Congress 2020, Stephen Johnston features the results from the monarchE study on abemaciclib and from the PALLAS trial with palbociclib, as adjuvant treatment in patients with HR positive HER2 negative early Breast Cancer.
He elaborates possible reasons why outcome in these trials was very different, and insists on the importance of risk factors assessment, as well as management of adverse events to improve treatment compliance.

Abstracts:

  • LBA12 - PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of palbociclib with adjuvant endocrine therapy versus adjuvant endocrine therapy alone for HR+/HER2- early breast cancer
  • LBA5_PR - Abemaciclib for the adjuvant treatment of high-risk early breast cancer
    Simultaneous publication: https://ascopubs.org/doi/full/10.1200/JCO.20.02514

This video was supported with educational grants from Bayer, Daiichi Sankyo and Novartis

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.